nach oben

Erschienen in:

04.05.2018 | Systemischer Lupus erythematodes | Leitthema

Kollagenosen im Kindes- und Jugendalter

verfasst von: C. Hinze, N. Wagner, Prof. Dr. K. Tenbrock

Erschienen in: Monatsschrift Kinderheilkunde | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Kollagenosen sind systemische Autoimmunerkrankungen, die verschiedene Organe betreffen können. Die Krankheitsbilder umfassen den systemischen Lupus erythematodes, die Dermatomyositis, die systemische Sklerose, das Sjögren-Syndrom, „Overlap“-Syndrome und undifferenzierte Kollagenosen. Aufgrund ihrer Seltenheit und ihrer Schwere stellen Kollagenosen im Kindesalter besondere Herausforderungen an Diagnostik und Therapie.

Klemperer P, Pollack AD, Baehr G (1984) Landmark article May 23, 1942: Diffuse collagen disease. Acute disseminated lupus erythematosus and diffuse scleroderma. By Paul Klemperer, Abou D. Pollack and George Baehr. JAMA 251(12:1593–1594CrossRef

Cervera R, Khamashta MA, Hughes GR (1990) ’Overlap’ syndromes. Ann Rheum Dis 49(11):947–948CrossRefPubMedPubMedCentral

LeRoy EC, Maricq HR, Kahaleh MB (1980) Undifferentiated connective tissue syndromes. Arthritis Rheum 23(3):341–343CrossRefPubMed

Wagner N (2009) Kutane Symptome rheumatischer Erkrankungen im Kindesalter. Hautarzt 60(3):200–207CrossRefPubMed

Pineles D, Valente A, Warren B, Peterson MG, Lehman TJ, Moorthy LN (2011) Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus 20(11):1187–1192CrossRefPubMed

Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58(2):556–562CrossRefPubMed

Feldman BM, Rider LG, Reed AM, Pachman LM (2008) Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371(9631):2201–2212CrossRefPubMed

Mizuno Y, Hara T, Hatae K, Hirano T, Ueda K, Nakamura N, Mizoguchi Y (1989) Recurrent parotid gland enlargement as an initial manifestation of Sjogren syndrome in children. Eur J Pediatr 148(5):414–416CrossRefPubMed

Mier RJ, Shishov M, Higgins GC, Rennebohm RM, Wortmann DW, Jerath R, Alhumoud E (2005) Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am 31(3):483–496CrossRefPubMed

10.

McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3(8):e297CrossRefPubMedPubMedCentral

11.

Armstrong DL, Zidovetzki R, Alarcon-Riquelme ME, Tsao BP, Criswell LA, Kimberly RP, Harley JB, Sivils KL, Vyse TJ, Gaffney PM et al (2014) GWAS identifies novel SLE susceptibility genes and explains the association of the HLA region. Genes Immun 15(6):347–354CrossRefPubMedPubMedCentral

12.

Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301(1):5–8CrossRefPubMed

13.

Norton WL, Velayos E, Robison L (1970) Endothelial inclusions in dermatomyositis. Ann Rheum Dis 29(1):67–72CrossRefPubMedPubMedCentral

14.

Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197(6):711–723CrossRefPubMedPubMedCentral

15.

Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA (2007) Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 56(11):3784–3792CrossRefPubMedPubMedCentral

16.

Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, Brohawn P, Kiener PA, Richman L, Fiorentino D et al (2011) Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 70(11):2029–2036CrossRefPubMed

17.

Monneaux F, Muller S (2002) Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum 46(6):1430–1438CrossRefPubMed

18.

Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 107(21):9813–9818CrossRefPubMed

19.

Malleson PN, Mackinnon MJ, Sailer-Hoeck M, Spencer CH (2010) Review for the generalist: The antinuclear antibody test in children – When to use it and what to do with a positive titer. Pediatr Rheumatol Online J 8:27CrossRefPubMedPubMedCentral

20.

Bertouch JV, Roberts-Thompson PJ, Feng PH, Bradley J (1983) C‑reactive protein and serological indices of disease activity in systemic lupus erythematosus. Ann Rheum Dis 42(6):655–658CrossRefPubMedPubMedCentral

21.

Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, Brunner HI, Ogawa R, Felson D, Ogdie A et al (2015) Distinctions between diagnostic and classification criteria? Arthritis Care Res 67(7):891–897CrossRef

22.

Tucker LB (2007) Making the diagnosis of systemic lupus erythematosus in children and adolescents. Lupus 16(8):546–549CrossRefPubMed

23.

Volpi S, Tsui J, Mariani M, Pastorino C, Caorsi R, Sacco O, Ravelli A, Shum AK, Gattorno M, Picco P (2017) Type I interferon pathway activation in COPA syndrome. Clin Immunol. https://doi.org/10.1016/j.clim.2017.10.001 PubMedCrossRef

24.

Crow YJ (2015) Type I interferonopathies: mendelian type I interferon up-regulation. Curr Opin Immunol 32:7–12CrossRefPubMed

25.

Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20–28CrossRefPubMed

26.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725CrossRefPubMed

27.

Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686CrossRefPubMedPubMedCentral

28.

Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82(5):299–308CrossRef

29.

Weening JJ, D’Agati VD, Schwartz MM et al, International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530CrossRefPubMed

30.

Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN) (2007) Therapieempfehlung zur Lupusnephritis bei Kindern und Jugendlichen. Monatsschr Kinderheilkd. https://doi.org/10.1007/s00112-007-1634-2 CrossRef

31.

Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, Hsu J, Klein-Gitelman M, Moorthy LN, Muscal E et al (2012) Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res 64(3):375–383CrossRef

32.

Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, Dolezalova P, Feldman BM, Kone-Paut I, Lahdenne P et al (2017) European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis 76(12):1965–1973CrossRefPubMed

33.

Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353(21):2219–2228CrossRefPubMed

34.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347CrossRefPubMed

35.

Kimball AB, Summers RM, Turner M, Dugan EM, Hicks J, Miller FW, Rider LG (2000) Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum 43(8):1866–1873CrossRefPubMed

36.

Bitnum S, Daeschner CW Jr., Travis LB, Dodge WF, Hopps HC (1964) Dermatomyositis. J Pediatr 64:101–131CrossRefPubMed

37.

Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76(2):329–340CrossRefPubMed

38.

Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T et al (2016) Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 387(10019):671–678CrossRefPubMed

39.

Dressler F, Huppertz HI (2006) Juvenile dermatomyositis. Z Rheumatol 65(7):587–590CrossRefPubMed

40.

Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM (2008) Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 59(2):222–226CrossRefPubMedPubMedCentral

41.

Robinson AB, Reed AM (2011) Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 7(11):664–675CrossRefPubMed

42.

Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T et al (2012) Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (hoboken) 64(4):546–553CrossRef

43.

Hinze CH, Oommen P, Dressler F, Schara U, Weller-Heinemann F, Brunner J, Föll D, Lainka E, Neudorf U, Schwarz T et al (2017) Development of consensus-based treat-to-target protocols for the management of juvenile dermatomyositis in Germany. Pediatr Rheumatol Online J 15(Suppl 2):287

44.

Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 69(5):911–923CrossRefPubMedPubMedCentral

45.

Zulian F, Balzarin M, Birolo C (2017) Recent advances in the management of juvenile systemic sclerosis. Expert Rev Clin Immunol 13(4):361–369CrossRefPubMed

46.

Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, Lehman TJ, de Oliveira SK, Susic G, Lyskina G et al (2006) Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum 54(12):3971–3978CrossRefPubMed

47.

Trang G, Steele R, Baron M, Hudson M (2012) Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 32(3):645–653CrossRefPubMed

48.

Distler JH, Feghali-Bostwick C, Soare A, Asano Y, Distler O, Abraham DJ (2017) Review: frontiers of Antifibrotic therapy in systemic sclerosis. Arthritis Rheumatol 69(2):257–267CrossRefPubMed

49.

Stiller M, Golder W, Doring E, Biedermann T (2000) Primary and secondary Sjogren’s syndrome in children – a comparative study. Clin Oral Investig 4(3):176–182CrossRefPubMed

Titel: Kollagenosen im Kindes- und Jugendalter
verfasst von: C. Hinze
N. Wagner
Prof. Dr. K. Tenbrock
Publikationsdatum: 04.05.2018
Verlag: Springer Medizin
Schlagwörter: Systemischer Lupus erythematodes
Kollagenosen
Juvenile Dermatomyositis
Mischkollagenose
Systemische Sklerodermie
Dermatomyositis
Sklerodermie
Lupus erythematodes
Lupusnephritis
Mycophenolat-Mofetil
Erschienen in: Monatsschrift Kinderheilkunde / Ausgabe 7/2018
Print ISSN: 0026-9298
Elektronische ISSN: 1433-0474
DOI: https://doi.org/10.1007/s00112-018-0498-y

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Kollagenosen im Kindes- und Jugendalter

Zusammenfassung

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2018

Für Sie gelesen

Mitteilungen der ÖGKJ

Mitteilungen der DGKJ

Erratum zu: Visuelle Wahrnehmungsstörungen

Suizid bei dualer Pharmakotherapie in der Adoleszenz

Warum beim Säugling die Schamhaare sprießten

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie